Cargando…
Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators
BACKGROUND: Direct-acting antivirals (DAAs) are increasingly accessible to patients with hepatitis C (HCV) worldwide and are being introduced through national health systems in sub-Saharan Africa. DAAs are highly efficacious when tested in controlled trials, yet patients treated outside of study set...
Autores principales: | Serumondo, Janvier, Penkunas, Michael J., Niyikora, Julienne, Ngwije, Alida, Kiromera, Athanase, Musabeyezu, Emmanuel, Umutesi, Justine, Umuraza, Sabine, Musengimana, Gentille, Nsanzimana, Sabin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298738/ https://www.ncbi.nlm.nih.gov/pubmed/32546216 http://dx.doi.org/10.1186/s12889-020-09000-0 |
Ejemplares similares
-
Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population
por: Umutesi, Justine, et al.
Publicado: (2019) -
Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study
por: Makuza, Jean Damascene, et al.
Publicado: (2020) -
Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program
por: Makuza, Jean Damascene, et al.
Publicado: (2019) -
“Waiting for DAAs”: A retrospective chart review of patients with untreated hepatitis C in Rwanda
por: Gupta, Neil, et al.
Publicado: (2017) -
Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda
por: Makuza, Jean Damascene, et al.
Publicado: (2019)